Description: Cabocyta is a pharmaceutical product that comes in the form of an injectable solution containing Cabazitaxel as its active ingredient. Cabazitaxel is a semi-synthetic taxane derivative with antineoplastic properties, primarily used in cancer treatment.

Composition: Each vial of Cabocyta contains 60 mg of Cabazitaxel as the active ingredient. The formulation also includes various excipients and stabilizers to maintain the stability and efficacy of the product.

Uses: Cabocyta is indicated for the treatment of metastatic hormone-refractory prostate cancer (mHRPC) in patients who have previously received docetaxel-based chemotherapy.

Usage and Dosage: Cabocyta is administered as an intravenous infusion. The recommended dosage is 25 mg/m² given every three weeks in combination with prednisone. The dosage may be adjusted based on individual patient factors, and healthcare professionals should follow the prescribing information for accurate dosing guidelines.

Storage Conditions: Cabocyta should be stored in accordance with the manufacturer’s recommendations. Typically, it is stored in a cool, dry place, away from direct sunlight, and at a controlled room temperature. The product should be kept out of reach of children.

Mechanism of Action: Cabazitaxel, the active ingredient in Cabocyta, inhibits microtubule depolymerization, disrupting the mitotic spindle function in cancer cells. This interference ultimately leads to cell cycle arrest and apoptosis, contributing to the antineoplastic effects observed in the treatment of prostate cancer.

Contraindications: Cabocyta is contraindicated in patients with a history of severe hypersensitivity reactions to Cabazitaxel or other drugs formulated with polysorbate 80. It is also contraindicated in patients with neutrophil counts less than 1,500 cells/mm³.

Interactions: Caution is advised when combining Cabocyta with drugs known to inhibit or induce the CYP3A enzyme system, as Cabazitaxel is metabolized by this pathway. Potential drug interactions should be thoroughly assessed, and dose adjustments may be necessary.

Adverse Reactions: Common adverse reactions associated with Cabocyta include neutropenia, anemia, diarrhea, fatigue, nausea, vomiting, and asthenia. Patients should be monitored for these side effects, and appropriate supportive care measures should be implemented as needed.

It is crucial to consult with a healthcare professional for personalized information and guidance on the use of Cabocyta, as individual patient circumstances may vary.